Abstract
Background Knowing the true infected and symptomatic case fatality ratios (IFR and CFR) for COVID-19 is of high importance for epidemiological model projections. A large correction factor is usually applied for missed cases. For the United State reported CFR of 5.96%, the estimated IFR values are 10–50-fold lower, justified by early reported CFR values of 0.1% to 0.5% in countries with more extensive testing. However, since then these values have risen 5 to 10-fold. We analyzed their age dependent CFR time courses to explain this increase and to determine whether a common factor can explain their CFRs.
Methods Age dependent time to fatality corrected CFR was calculated using two independent methods. A linear model was developed that predicts CFR based on age dependent CFR coefficients and the age distribution of cases. The model was tested by a linear regression of each country’s CFR against case percentage of 70 years and over. The model was further tested by calculating the percent of the population in New York City who have been infected.
Results Corrected CFR values ranged from 0.58% to 5.0%. The large majority of CFR variation was explained by case age distribution above 70 years old. Using the CFR derived from the linear model we predicted between 14.7% and 22% of the adult population in NYC had been infected by COVID-19, in agreement with random testing studies (15.3% – 21%).
Conclusions The large rise in the reported CFR is due to the delay time between infection/diagnosis and fatality with COVID-19. The linear model based on their age specific CFR values provides an alternative method for calculating the true CFR in other regions. Most of the variation in CFR between countries was dependent on case age distribution, which must be considered in measures for mitigating the extensive impacts of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive any external funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is available upon reasonable request to the authors.
